Teva Neuroscience Launches Spanish Parkinson's Disease Patient and Caregiver Web Site

Tuesday, September 30, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

KANSAS CITY, Mo., Sept. 29 In recognition of HispanicHeritage Month, Teva Neuroscience, Inc., marketers of the once-dailyParkinson's disease (PD) drug AZILECT (R) (rasagiline tablets), todayannounced the launch of the Spanish version of their patient and caregiverresource Web site, The Spanish Web site wascreated to provide important information and resources to members of theHispanic community, living in the U.S., who are affected by PD, an age-relateddegenerative disorder of the brain.

"Unfortunately, there are not a lot of resources for Spanish-speakingpatients dealing with Parkinson's disease," said Dr. Ramon L. Rodriguez,director of clinical services at the University of Florida's MovementDisorders Center. "Even though there is no cure for Parkinson's, it isimportant for patients to learn how to live well through a combination ofactivities and treatments that can help control the symptoms of the disease."

The Spanish Web site,, is a comprehensiveresource that provides important information to help patients and familieswith the physical and emotional effects of PD. Spanish-speaking visitors willbe able to access a wide range of information and resources, including:

Additionally, visitors will have access to a downloadable version of therecently released "Hacia adelante" resource guide. The easy-to-use guide is auseful tool that helps people affected by PD understand more about thedisease, learn how to live well despite the diagnosis, and research varioustreatment options.

"We are pleased to bring these much needed resources to theSpanish-speaking community living in the U.S.," said Teva Neuroscience productmanager, Mike Sheehy. "We believe it is important to provide Spanish-languagematerials and information that help people manage diseases, such as PD, tothis important and growing community."

Teva Neuroscience is headquartered in Kansas City, MO. For additionalinformation about Teva's Spanish resources for PD or AZILECT, visit

About AZILECT(R)(rasagiline tablets)

AZILECT is indicated for the treatment of the signs and symptoms ofParkinson's disease both as initial therapy alone and to be added to levodopalater in the disease. The effectiveness of AZILECT was shown in patients withearly PD who were receiving AZILECT as initial therapy alone and who were notreceiving any other PD therapy. The effectiveness of AZILECT as adjuncttherapy was shown in patients with PD who were treated with levodopa.

You are encouraged to report negative side effects of prescription drugsto the FDA. Visit, or call 1-800-FDA-1088.

About Parkinson's Disease

Parkinson's disease is an age-related degenerative disorder of the brain.Symptoms can include tremor, stiffness, slowness of movement, and impairedbalance. An estimated 1 million Americans have the disease, which usuallyaffects people over the age of 60.

About Teva

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA), headquartered inIsrael, is among the top 20 pharmaceutical companies in the world. The companydevelops, manufactures, and markets innovative and generic humanpharmaceuticals and active pharmaceutical ingredients. Over 80 percent ofTeva's sales are in North America and Europe. Teva's innovative R&D focuses ondeveloping novel drugs for diseases of the central nervous system.

Teva's U.S. innovative product marketing subsidiary, Teva Neuroscience,Inc., promotes AZILECT in the United States. AZILECT is a registered trademarkof Teva Pharmaceutical Industries Ltd. Please visit foradditional important information.

Please see enclosed additional important information.-- Basic disease information and treatment options -- Signs and symptoms of the disease -- Tips on living well through a combination of treatment, activities, and support -- Downloadable worksheets and links to various other resources -- Caregiver information

SOURCE Teva Neuroscience, Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store